

# MALT Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/M9CD34C18E11EN.html>

Date: May 2024

Pages: 129

Price: US\$ 6,499.00 (Single User License)

ID: M9CD34C18E11EN

## Abstracts

The 7 major malt lymphoma markets reached a value of US\$ 1.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 2.8 Billion by 2034, exhibiting a growth rate (CAGR) of 7.98% during 2024-2034.

The MALT lymphoma market has been comprehensively analyzed in IMARC's new report titled "MALT Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". MALT (mucosa-associated lymphoid tissue) lymphoma is a type of non-Hodgkin lymphoma that originates from the lymphoid tissue in mucosal sites, such as the stomach, lungs, salivary glands, thyroid, etc. Some of the common symptoms are painless swelling of lymph nodes in the neck, armpits, groin, etc., which may be the only visible sign of the disease. If MALT lymphoma affects the stomach, numerous indications, like abdominal pain, indigestion, nausea, vomiting, etc., may occur. In cases involving the lungs, various symptoms, including coughing, shortness of breath, chest discomfort, etc., may be present. The diagnosis of the ailment typically consists of a combination of clinical evaluation, imaging studies, and a tissue biopsy. The process begins with a thorough medical history review and physical examination by a healthcare professional, who may identify enlarged lymph nodes or other abnormalities. Numerous imaging techniques, such as computed tomography (CT) scans or positron emission tomography (PET) scans, are utilized to assess the extent of disease involvement and identify any areas of concern. Additionally, various laboratory tests, including immunohistochemistry and molecular testing, may be conducted to aid in the diagnosis and subtype classification of MALT lymphoma.

The escalating cases of genetic alteration leading to dysregulation of cellular processes involved in cell survival and proliferation are primarily driving the MALT lymphoma

market. In addition to this, the rising prevalence of several associated risk factors, including persistent inflammation caused by chronic infections, immune system dysfunction, occupational exposure to certain chemicals like benzene, etc., is also bolstering the market growth. Furthermore, the inflating adoption of stem cell transplantation for replacing the diseased bone marrow with healthy stem cells to restore the body's ability to produce normal blood cells is acting as another significant growth-inducing factor. Additionally, the escalating application of radiation therapy, which utilizes high-energy beams to target and destroy cancer cells in areas that cannot be easily surgically removed, such as the salivary glands and lungs, is also creating a positive outlook for the market. Apart from this, the rising utilization of non-invasive imaging techniques, including positron emission tomography-computed tomography (PET-CT) and magnetic resonance imaging (MRI), for improved visualization and accurate staging of the ailment is expected to drive the MALT lymphoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the MALT lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for MALT lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the MALT lymphoma market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France  
United Kingdom  
Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario  
Historical, current, and future performance of the MALT lymphoma market  
Historical, current, and future performance of various therapeutic categories in the market  
Sales of various drugs across the MALT lymphoma market  
Reimbursement scenario in the market  
In-market and pipeline drugs  
Competitive Landscape:  
This report also provides a detailed analysis of the current MALT lymphoma marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance  
Key Questions Answered in this Report:  
Market Insights

How has the MALT lymphoma market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the MALT lymphoma market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the MALT lymphoma market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of MALT lymphoma across the seven major markets?

What is the number of prevalent cases (2018-2034) of MALT lymphoma by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of MALT lymphoma by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with MALT lymphoma across the seven major markets?

What is the size of the MALT lymphoma patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of MALT lymphoma?

What will be the growth rate of patients across the seven major markets?

### MALT Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for MALT lymphoma drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the MALT lymphoma market?

What are the key regulatory events related to the MALT lymphoma market?

What is the structure of clinical trial landscape by status related to the MALT lymphoma market?

What is the structure of clinical trial landscape by phase related to the MALT lymphoma market?

What is the structure of clinical trial landscape by route of administration related to the MALT lymphoma market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 MALT LYMPHOMA - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 MALT LYMPHOMA - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 MALT LYMPHOMA - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Diagnosed Cases (2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Diagnosed Cases (2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Diagnosed Cases (2018-2034)
  - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Diagnosed Cases (2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Diagnosed Cases (2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Diagnosed Cases (2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Diagnosed Cases (2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (2018-2034)

## **8 MALT LYMPHOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 MALT LYMPHOMA - UNMET NEEDS**

## **10 MALT LYMPHOMA - KEY ENDPOINTS OF TREATMENT**

## **11 MALT LYMPHOMA - MARKETED PRODUCTS**

- 11.1 List of MALT Lymphoma Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Drug Name – Company Name
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.



## **12 MALT LYMPHOMA - PIPELINE DRUGS**

### 12.1 List of MALT Lymphoma Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 Drug Name – Company Name

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

## **13. MALT LYMPHOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. MALT LYMPHOMA – CLINICAL TRIAL LANDSCAPE**

### 14.1 Drugs by Status

### 14.2 Drugs by Phase

### 14.3 Drugs by Route of Administration

### 14.4 Key Regulatory Events

## **15 MALT LYMPHOMA - MARKET SCENARIO**

### 15.1 Market Scenario - Key Insights

### 15.2 Market Scenario - Top 7 Markets

#### 15.2.1 MALT Lymphoma - Market Size

##### 15.2.1.1 Market Size (2018-2023)

##### 15.2.1.2 Market Forecast (2024-2034)

#### 15.2.2 MALT Lymphoma - Market Size by Therapies

##### 15.2.2.1 Market Size by Therapies (2018-2023)

##### 15.2.2.2 Market Forecast by Therapies (2024-2034)

### 15.3 Market Scenario - United States

#### 15.3.1 MALT Lymphoma - Market Size

##### 15.3.1.1 Market Size (2018-2023)

##### 15.3.1.2 Market Forecast (2024-2034)

#### 15.3.2 MALT Lymphoma - Market Size by Therapies

##### 15.3.2.1 Market Size by Therapies (2018-2023)

##### 15.3.2.2 Market Forecast by Therapies (2024-2034)

#### 15.3.3 MALT Lymphoma - Access and Reimbursement Overview

## 15.4 Market Scenario - Germany

### 15.4.1 MALT Lymphoma - Market Size

#### 15.4.1.1 Market Size (2018-2023)

#### 15.4.1.2 Market Forecast (2024-2034)

### 15.4.2 MALT Lymphoma - Market Size by Therapies

#### 15.4.2.1 Market Size by Therapies (2018-2023)

#### 15.4.2.2 Market Forecast by Therapies (2024-2034)

### 15.4.3 MALT Lymphoma - Access and Reimbursement Overview

## 15.5 Market Scenario - France

### 15.5.1 MALT Lymphoma - Market Size

#### 15.5.1.1 Market Size (2018-2023)

#### 15.5.1.2 Market Forecast (2024-2034)

### 15.5.2 MALT Lymphoma - Market Size by Therapies

#### 15.5.2.1 Market Size by Therapies (2018-2023)

#### 15.5.2.2 Market Forecast by Therapies (2024-2034)

### 15.5.3 MALT Lymphoma - Access and Reimbursement Overview

## 15.6 Market Scenario - United Kingdom

### 15.6.1 MALT Lymphoma - Market Size

#### 15.6.1.1 Market Size (2018-2023)

#### 15.6.1.2 Market Forecast (2024-2034)

### 15.6.2 MALT Lymphoma - Market Size by Therapies

#### 15.6.2.1 Market Size by Therapies (2018-2023)

#### 15.6.2.2 Market Forecast by Therapies (2024-2034)

### 15.6.3 MALT Lymphoma - Access and Reimbursement Overview

## 15.7 Market Scenario - Italy

### 15.7.1 MALT Lymphoma - Market Size

#### 15.7.1.1 Market Size (2018-2023)

#### 15.7.1.2 Market Forecast (2024-2034)

### 15.7.2 MALT Lymphoma - Market Size by Therapies

#### 15.7.2.1 Market Size by Therapies (2018-2023)

#### 15.7.2.2 Market Forecast by Therapies (2024-2034)

### 15.7.3 MALT Lymphoma - Access and Reimbursement Overview

## 15.8 Market Scenario - Spain

### 15.8.1 MALT Lymphoma - Market Size

#### 15.8.1.1 Market Size (2018-2023)

#### 15.8.1.2 Market Forecast (2024-2034)

### 15.8.2 MALT Lymphoma - Market Size by Therapies

#### 15.8.2.1 Market Size by Therapies (2018-2023)

#### 15.8.2.2 Market Forecast by Therapies (2024-2034)

- 15.8.3 MALT Lymphoma - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 MALT Lymphoma - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 MALT Lymphoma - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 MALT Lymphoma - Access and Reimbursement Overview

## **16 MALT LYMPHOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 MALT LYMPHOMA MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 MALT LYMPHOMA MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: MALT Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/M9CD34C18E11EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M9CD34C18E11EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

